Etanercept biosimilar - AryoGen Pharmed

Drug Profile

Etanercept biosimilar - AryoGen Pharmed

Alternative Names: Altebrel

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator AryoGen Biopharma
  • Developer AryoGen Pharmed
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Feb 2014 Launched prior to this date for Ankylosing spondylitis in Iran (SC)
  • 27 Feb 2014 Launched prior to this date for Juvenile rheumatoid arthritis in Iran (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top